Tags

Type your tag names separated by a space and hit enter

Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
Vaccine. 2004 Jun 02; 22(17-18):2103-5.V

Abstract

Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX trade mark, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX trade mark. Similar incidence data is required from other countries for comparison.

Authors+Show Affiliations

C/- Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CBI 9PT, UK. scott.kitchener@acambis.com

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15149765

Citation

Kitchener, Scott. "Viscerotropic and Neurotropic Disease Following Vaccination With the 17D Yellow Fever Vaccine, ARILVAX." Vaccine, vol. 22, no. 17-18, 2004, pp. 2103-5.
Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine. 2004;22(17-18):2103-5.
Kitchener, S. (2004). Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine, 22(17-18), 2103-5.
Kitchener S. Viscerotropic and Neurotropic Disease Following Vaccination With the 17D Yellow Fever Vaccine, ARILVAX. Vaccine. 2004 Jun 2;22(17-18):2103-5. PubMed PMID: 15149765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. A1 - Kitchener,Scott, PY - 2004/01/13/received PY - 2004/01/19/accepted PY - 2004/5/20/pubmed PY - 2005/1/19/medline PY - 2004/5/20/entrez SP - 2103 EP - 5 JF - Vaccine JO - Vaccine VL - 22 IS - 17-18 N2 - Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX trade mark, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX trade mark. Similar incidence data is required from other countries for comparison. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15149765/Viscerotropic_and_neurotropic_disease_following_vaccination_with_the_17D_yellow_fever_vaccine_ARILVAX_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264410X04000702 DB - PRIME DP - Unbound Medicine ER -